C
이뮨온시아
424870KOSDAQ자연과학 및 공학 연구개발업52.5 / 100
Reference Date: 2026-04-13
Financial Score18.5 / 40
News Sentiment15.0 / 25
Momentum4.0 / 20
Disclosure15.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 19.6% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Imunovia specializes in developing antibody-based immunotherapy drugs, with key assets including Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies. The company is conducting Phase 2 trials for IMC-001 in NK/T cell lymphoma and TMB-High solid tumors, aiming for domestic commercialization and the development of a global blockbuster drug.
Number of Employees
22people
Average Salary
103.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
18.74Industry Average 3.820.0Point
4.9x industry avg (risky)
ROE
-114.40Industry Average -32.113.5Point
3.6x industry avg (excellent)
Debt Ratio
1.66Industry Average 7.528.0Point
Half of industry avg (excellent)
Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
0.0 / 4
Detailed News Sentiment
4 totalPositive 1Neutral 0Negative 0Average Sentiment Score 90
- Positive이뮨온시아, 림프종 임상2상서 ORR 79%·CR 63%…"압도적 성과...
이뮨온시아는 재발·불응성 NK/T세포 림프종을 적응증으로 하는 'PD-L1' 항체 신약 '덴버스토투그'의 임상 2상에서 ORR 79%, CR 63%라는 압도적인 성과를 발표했습니다.
Detailed Momentum
52-week position3.0Point
52w lower range (24%)
Current 7,160Won52-week high 15,38052-week low 4,540
1-month return0.0Point
1m -19.55% (strong drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
11 totalPositive 3Neutral 8Negative 0
- Positive권리락 (유상증자)2026-04-02
- Neutral효력발생안내( 2026.3.18. 제출 증권신고서(지분증권) )2026-04-02
- Neutral[발행조건확정]증권신고서(지분증권)2026-04-02
- Positive[기재정정]주요사항보고서(유상증자결정)2026-04-02
- Positive유상증자1차발행가액결정2026-04-02